Articles From: UPDATE: Church & Dwight 1st-Quarter Profit Up as Sales Improve to Verenium Corporation to Announce First Quarter 2013 Financial Results

--Earnings rise over 10% --Revenue jumps, margins improve --2Q guidance below analysts' expectations (Adds comments from company's conference call) By Anna Prior and Karen Talley Church & Dwight Co.'s (CHD) first-quarter earnings rose 12% as the consumer products maker reported a jump in revenue and improving margins, helping results beat estimates.

-- Cigna earnings pressured by one-time charge, but adjusted results top Street --

-CME profit falls to $235.8 million , or 71 cents a share -Trading activity rises 1% over first quarter of 2012, though averge fee slips 3% -Lighter trade in agricultural, energy contracts, which carry higher fees (Updates with executive comment, additional detail on results, April trading volume.) By Mia Lamar and Jacob Bunge CME Group Inc.'s (CME) first-quarter earnings fell 12%, hurt by a decline in trading fees.

-- Estee Lauder's fiscal third-quarter earnings rose sharply --Earnings beat company's own forecast --Company raised full-year earnings guidance (Adds comments from CEO interview, conference call, analyst comments and stock quote, throughout.) By Anna Prior Affluent consumers continued to shell out for Estee Lauder Cos .' (EL) high-end beauty products as the company reported an increase in sales across all three of its geographic regions in its fiscal third quarter, though the pace of its growth appears to be slowing slightly as global economic headwinds persist.

--Sales rose more than 8% as Gilead's newest HIV drugs gained traction --Profits grew 63% from a year earlier, helped by lower acquisition costs --Gilead got an FDA letter related to laboratory records, other concerns (Updated to add details and company comment.) By Joseph Walker Gilead Sciences Inc.'s (GILD) first-quarter sales rose a disappointing 8.4% as increased traction for the newer additions to the company's HIV franchise wasn't enough to offset customers stocking up on its antiviral drugs ahead of price increases implemented earlier this year.

(Updates with revised figure of $66 billion for market cap of Glencore Xstrata, in fourth paragraph.) By Diana Kinch LONDON--Mining and metals group Glencore International PLC has completed its long-awaited merger with Xstrata PLC to form the world's fourth biggest mining company and the world's biggest commodities trader.

--Newly merged company's CEO says focus on integrating Glencore and Xstrata , squeezing out every ounce of profit --The CEO says he expects to fire a "big amount" of Xstrata middle managers --Also, the company will be on the lookout for the next deal, though it will probably go slow on major acquisitions (Adds details from interview with Glencore's CEO throughout.) By John W.

--Operating Chief Brian Krzanich was considered a front-runner --Krzanich succeeds CEO Paul Otellini --

(Adds statement from Simon Property spokesman and stock price) By A.D. Pruitt An influential corporate governance firm is calling on shareholders of Simon Property Group Inc. (SPG) to reject Chief Executive David Simon's compensation package for a second year in a row.

--Kellogg sees costs falling in second half of 2013 --Kellogg CEO says cereal maker will focus on recouping lost margins, not cutting prices --Shares fall as first-quarter earnings miss expectations (Adds details from earnings call and interview with CEO.) By Paul Ziobro Kellogg Co.

--Kraft's first-quarter net falls on higher interest expenses and restructuring charges --Cost cuts, sales growth help Kraft top Wall Street expectations --Company backs full-year outlook (Adds details from release, including Kraft's cost savings and marketing plans.

(Adds Intel comment in fourth paragraph.) By Joseph Checkler Lehman Brothers Holdings Inc. is suing Intel Corp.

(Updates throughout with detail, background.) By Jacob Bunge and Jerry Dicolo The U.S. futures market regulator on Thursday named Ron Eibschutz as the previously unidentified broker who allegedly received leaked trading data from former staffers of the New York Mercantile Exchange .

--Teva's sales and earnings fall on increased competition --Company points to new product launches --CEO Jeremy Levin says investors haven't yet become comfortable with new strategy (Updates throughout with details and company comment.) By Joseph Walker Teva Pharmaceutical Industries Ltd.'s (TEVA) first-quarter earnings fell 27% as the drug maker saw a sharp drop in generic-medicine sales and increased competition for its alertness drug Provigil.

-- Mine shutdown in mid-May to affect 149 workers --

(Adds comments from earnings call and context in paragraphs 4-7) --Valeant CEO won't comment on rumored Actavis talks --Won't preclude acquisition targets if they meet strategy --Some analysts question such a deal By Judy McKinnon and Ben Dummett Valeant Pharmaceuticals International Inc.'s (VRX) first-quarter loss widened, but excluding one-time items, results beat analyst expectations and the company hiked its earnings guidance for the year.

The UPS (NYSE: UPS) Board of Directors today declared a regular quarterly dividend of $0.62 per share on all outstanding Class A and Class B shares.

Shareowners of UPS (NYSE: UPS) today elected a Board of Directors for a one-year term and ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accountants.

Urstadt Biddle Properties Inc. (NYSE: UBA and UBP) announced today that it has acquired The Village Shopping Center in New Providence, NJ for $34,850,000. The property was purchased subject to an existing mortgage in the amount of $18,980,000 that requires payments of principal and interest at a fixed rate of 5.6803% per annum.

USA Compression Partners, LP (NYSE: USAC) announced today that Matthew C.

USA Mobility, Inc. (Nasdaq: USMO) , a leading provider of wireless messaging, mobile voice and data and unified communications solutions , today announced it will report operating results for the first quarter ended March 31, 2013 on Thursday, May 9, 2013 at approximately 4:30 p.m. Eastern Time (ET). In addition, the Company plans to host a conference call for investors on its first quarter results at 10:00 a.m. ET on Friday, May 10, 2013.

USA Technologies, Inc. (NASDAQ: USAT) (“USAT”), a leader of wireless, cashless payment and M2M telemetry solutions for small-ticket, self-serve retailing industries is showcasing ePort Mobile TM —an extension of USAT’s flagship ePort Connect® service—at the 2013 ETA Annual Meeting & Expo , at the New Orleans Convention Center in New Orleans.

Company Welcomes Tyler McGill, Karina Bryant and Crystal Manning to Team USANA SALT LAKE CITY , May 2, 2013 /PRNewswire/ --  USANA Health Sciences Inc. (NYSE: USNA) , a global nutritional supplements company, has partnered with Summer Game medalists swimmer Tyler McGill ( United States ) and mixed martial artist Karina Bryant (judo, Great Britain ), as well as track and field star Crystal Manning (triple jump, United States ). Team USANA's newest members join more than 600 world-class athletes who take USANA's NSF and HFL- tested nutritional products .

Recognized with over 100 awards, the official website for the State of Utah ( http://Utah.gov ), shows off a new homepage boasting major enhancements.

Valeant Pharmaceuticals Provides Efinconazole Update Canada NewsWire LAVAL, Quebec , May 2, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that we agreed this afternoon that the launch of efinaconazole, our topical product candidate for the treatment of onychomycosis, will not occur until after the September 2013 arbitration hearing to resolve the breach of contract dispute with Anacor Pharmaceuticals (NASDAQ: ANAC) .

LAVAL, Quebec , May 2, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that we agreed this afternoon that the launch of efinaconazole, our topical product candidate for the treatment of onychomycosis, will not occur until after the September 2013 arbitration hearing to resolve the breach of contract dispute with Anacor Pharmaceuticals (NASDAQ: ANAC) .

LAVAL, Quebec , May 2, 2013 /PRNewswire/ --   2013 First Quarter Total Revenue $1.068 billion ; an increase of 25% over the prior year   2013 First Quarter Product Sales $1.039 billion ; an increase of 38% over the prior year   Organic growth (same store sales) was 6%, excluding the impact from generics, primarily BenzaClin and Cesamet   Pro forma organic growth was 4%, excluding the impact from generics, primarily BenzaClin and Cesamet   2013 First Quarter GAAP EPS Loss of $0.09 ; Cash EPS $1.30 , an increase of 43% over the prior year, excluding one-time items in 2012 first quarter   2013 First Quarter GAAP Operating Cash Flow $255 million ; Adjusted Operating Cash Flow $345 million ; an increase of 35% over the prior year, excluding one-time items in 2012 first quarter   2013 Guidance for Cash EPS raised to $5.55 to $5.85 despite entry of Zovirax generic ointment Valeant Pharmaceuticals International,

Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results Canada NewsWire LAVAL, Quebec, May 2, 2013 /CNW/ - 2013 First Quarter Total Revenue $1.068 billion; an increase of 25% over the prior year 2013 First Quarter Product Sales $1.039 billion; an increase of 38% over the prior year Organic growth (same store sales) was 6%, excluding the impact from generics, primarily BenzaClin and Cesamet Pro forma organic growth was 4%, excluding the impact from generics, primarily BenzaClin and Cesamet 2013 First Quarter GAAP EPS Loss of $0.09; Cash EPS $1.30, an increase of 43% over the prior year, excluding one-time items in 2012 first quarter 2013 First Quarter GAAP Operating Cash Flow $255 million; Adjusted Operating Cash Flow $345 million; an increase of 35% over the prior year, excluding one-time items in 2012 first quarter 2013 Guidance for Cash EPS raised to $5.55 to $5.85 despite entry of Zovirax generic

Valeant Pharmaceuticals International Inc.'s (VRX) first-quarter loss widened, but excluding one-time items, results beat analyst expectations and the company hiked its earnings guidance for the year.

SAN DIEGO , May 2, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM) , a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release first quarter 2013 financial results on Thursday, May 9, 2013 after market close.